Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

(2009) Nancy A. Rigotti et al.   ADDICTION

From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour

(2009) Pradeep J. Nathan et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo

(2009) Frank L. Greenway et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis

(2009) K. Johansson et al.   Obesity Reviews

The psychiatric side-effects of rimonabant

(2009) Fabrício A. Moreira et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

(2008) Jean-Pierre Després et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Opioidergic projections to sleep-active neurons in the ventrolateral preoptic nucleus

(2008) Mary-Ann Greco et al.   BRAIN RESEARCH

The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake

(2008) Carol Addy et al.   Cell Metabolism

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES CARE

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

(2008) Luc F. Van Gaal et al.   EUROPEAN HEART JOURNAL

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Health

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of the weight-loss drug rimonabant

(2008) Jean-Pierre Després et al.   LANCET

Efficacy and safety of the weight-loss drug rimonabant – Authors' reply

(2008) Arne Astrup et al.   LANCET

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

(2008) Arne Astrup et al.   LANCET

5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis

(2008) Yong Xu et al.   NEURON

Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease

(2008) Arne Astrup et al.   Obesity

Rational Design of a Combination Medication for the Treatment of Obesity

(2008) Frank L. Greenway et al.   Obesity

Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women

(2008) Steven R. Smith et al.   Obesity

Serotonin 5-HT2CReceptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 Receptors

(2007) Daniel D. Lam et al.   ENDOCRINOLOGY

Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomised study

(2007) D.N. Kiortsis et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES